Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines

  title={Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines},
  author={Baoying Huang and Lianpan Dai and Hui Wang and Zhong-yu Hu and Xiaoming Yang and Wenjie Tan and George Fu Gao},
Recently, the emerged and rapidly spreading SARS-CoV-2 variant of concern (VOC) 501Y.V2 with 10 amino acids in spike protein were found to escape host immunity induced by infection or vaccination. Global concerns have been raised for its potential to affect vaccine efficacy. Here, we evaluated the neutralization activities of two vaccines developed in China against 501Y.V2. One is licensed inactivated vaccine BBIBP-CorV and the other one is recombinant dimeric receptor-binding domain (RBD… 

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

RFN, adjuvanted with a liposomal-QS21 formulation (ALFQ), elicits humoral and cellular immune responses exceeding those of current vaccines in terms of breadth and potency and protects against high-dose respiratory tract challenge.

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

The evaluation of a ferritin nanoparticle vaccine displaying the receptor-binding domain of the SARS-CoV-2 spike protein (RFN) adjuvanted with Army Liposomal Formulation QS-21 (ALFQ) supports consideration of RFN for vaccine development against multiple concerning members of the Sarbecovirus subgenus of Betacoronaviruses.

Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines

Though in vitro neutralization studies are a valuable tool to estimate the performance of vaccines against the backdrop of emerging variants, the results must be interpreted with caution and corroborated with field-effectiveness studies.

Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants

This article reviews the candidate targets, vaccine types, research and development status, progress of SARS-CoV-2 vaccines, and the effectiveness of neutralizing antibodies against Sars-Co V-2 mutants induced by these vaccines, to provide a reference for follow-up research and prevention.

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

A novel RBD homodimer vaccine developed as a SARS-CoV-2 vaccine candidate elicited strong immune response in both rodents and non-human primates and may serve as a safe, effective, and low-cost Sars- CoV- 2 vaccine candidate.

Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

This review summarizes with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof.

The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?

This review summarized the current understanding on five notable genetic variants, i.e., D614G, Cluster 5, VOC 202012/01, 501Y.V2 and P.1, and discussed the potential impact of these variants on the virus transmission, pathogenesis and vaccine efficacy.

SARS-CoV-2 variants, spike mutations and immune escape

The literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, is summarized, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discussed in the context of observed mutation frequencies in global sequence datasets.



mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Low neutralization from convalescent serum by pseudovirus neutralization (PsVN) assays and resistance to certain monoclonal antibodies is found in subjects immunized with Moderna mRNA-1273 and despite the observed decreases, the GMT of VSV PsVN titers in human vaccinee sera against the B.1.1 .1.351 variant remained at ~1/300.

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage, and new variants with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 501Y.V2 shows substantial or complete escape from neutralizing antibodies in COVID-19 convalescent plasma, highlighting the prospect of reinfection with antigenically distinct variants and may foreshadow reduced efficacy of current spike-based vaccines.

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Viral targets for vaccines against COVID-19

As the world races to develop vaccines against SARS-CoV-2, Dai and Gao highlight which viral targets are best to include in a vaccine and how this impacts the induced immune response and the safety and efficacy of a vaccine.

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.

Reemergent Cases of COVID-19 — Xinfadi Wholesales Market, Beijing Municipality, China, June 11, 2020

The genome sequences of these Xinfadi strains provide strong evidence that the reemergent of COVID-19 cases in Beijing may be caused by an imported source of infections, suggesting that it is not continuous transmission of the local CO VID-19 virus strain.